Home » Stocks » Adynxx

Adynxx, Inc. (ADYX)

Stock Price: $0.140 USD -0.140 (-50.00%)
Updated Aug 14, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 813,120
Revenue (ttm) n/a
Net Income (ttm) -8.73M
Shares Out 5.81M
EPS (ttm) -1.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $0.140
Previous Close $0.280
Change ($) -0.140
Change (%) -50.00%
Day's Open 5.880
Day's Range 0.140 - 0.300
Day's Volume 2,616
52-Week Range 0.140 - 2.690

More Stats

Market Cap 813,120
Enterprise Value 9.71M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.81M
Float 1.00M
EPS (basic) -4.03
EPS (diluted) -1.82
FCF / Share -1.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 25,825
Short Ratio 2.86
Short % of Float 3.96%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -6.28M
Net Income -8.73M
Free Cash Flow -6.98M
Net Cash -8.90M
Net Cash / Share -1.53
Gross Margin n/a
Operating Margin n/a
Profit Margin -1,481.70%
FCF Margin n/a
ROA -192.35%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$16.80*
Low
16.8
Current: $0.140
High
16.8
Target: 16.80
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2018201720162015201420132012201120102009
Revenue2.222.0216.2912.184.791.801.231.831.321.45
Revenue Growth9.76%-87.61%33.81%154.42%166.23%46.32%-32.94%38.88%-8.93%-
Gross Profit0.500.1810.246.951.52-0.25-0.61-0.09-0.52-0.23
Operating Income-5.30-4.76-41.89-30.98-25.19-20.13-4.90-13.85-2.72-0.74
Net Income-8.42-25.71-28.24-26.02-25.45-21.98-4.91-13.85-3.10-0.76
Shares Outstanding0.820.720.470.380.240.120.090.080.060.03
Earnings Per Share-10.26-35.94-60.60-67.80-104.40-188.40-54.60-183.75-52.50-26.25
Operating Cash Flow-9.71-10.67-18.34-21.62-13.29-4.77-1.97-2.20-1.71-0.16
Capital Expenditures--0.18-0.89-0.42-0.01-0.05-0.09-0.29-0.05-0.03
Free Cash Flow-9.71-10.85-19.23-22.05-13.30-4.82-2.05-2.49-1.77-0.19
Cash & Equivalents1.942.185.5826.0816.7712.100.260.261.760.18
Total Debt8.31-11.5412.13------
Net Cash / Debt-6.372.18-5.9613.9516.7712.100.260.261.760.18
Assets1.9832.9454.5089.7529.7217.4513.7314.0325.206.71
Liabilities38.5117.2722.4137.337.213.501.580.390.380.18
Book Value-36.5315.6732.0952.4322.5113.9512.1513.6324.826.53
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Adynxx, Inc.
Country United States
Employees 6
CEO Rick Orr

Stock Information

Ticker Symbol ADYX
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: ADYX

Description

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.